Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat
- Mar 1, 2022
- 1 min read
Updated: Sep 13, 2022
Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk, high-reward IL-12 target — doing it in a deal with repeat collaborator and NK cell engager player Dragonfly Therapeutics.
As part of that deal, Vessey handed over $475 million in near-term cash in exchange for a global license for Dragonfly’s extended half-life cytokine DF6002 — a monovalent, IL-12 immunoglobulin Fc fusion protein designed to spur a targeted immune response.
Rupert Vessey's $475M bet on Dragonfly's DF6002 shows real conviction in IL-12 as an NK cell engager. I've been https://ai-3d-modeling.com
Rupert Vessey's IL-12 play with Dragonfly's DF6002 is a bold $475M bet on NK cell engagers. With DF6002's extended half-life, I'm curious how it stacks up in efficacy — I've been tracking similar fusions, and this one looks promising. https://ai-3d-model-generator.com
Rupert Vessey's $475M bet on Dragonfly's DF6002 is a bold play on IL-12, but extended half-life cytokines still face tough safety hurdles. I've been following similar Fc fusion approaches — curious how they plan to mitigate cytokine release with this monovalent format. https://nemotron-ai.com
DF6002's half-life extension is a clever play on IL-12, but $475M for a global license is steep. Given BMS's recent M&A pace, I'm curious how this compares to their other biotherapeutic partnerships. I've been tracking similar fusion protein approaches https://glbviewer.com
Rupert Vessey's bet on Dragonfly's DF6002 is exactly the kind of high-risk play that could redefine cytokine therapy — but with $475 million on the line, execution is everything. I've been following NK cell engager pipelines closely and would love to see more data on DF6002's half-life advantages. https://image-to-stl.com